| PD-1/PD-L1抑制剂治疗中晚期非小细胞肺癌疗效及安全性的Meta分析 |
| |
| 引用本文： | 姜爱民,程 宇. PD-1/PD-L1抑制剂治疗中晚期非小细胞肺癌疗效及安全性的Meta分析[J]. 现代肿瘤医学, 2020, 0(20): 3555-3560. DOI: 10.3969/j.issn.1672-4992.2020.20.019 |
| |
| 作者姓名： | 姜爱民 程 宇 |
| |
| 作者单位： | 沈阳医学院附属中心医院肿瘤内科，辽宁 沈阳 110024 |
| |
| 摘 要： | 目的:运用Meta分析方法系统评价PD-1/PD-L1抑制剂治疗中晚期非小细胞肺癌（NSCLC）的疗效及安全性。方法:检索CNKI、万方、Pubmed和Cochrane图书馆数据库，提取数据并进行核对，利用RevMan5.3软件的Cochrane偏倚风险工具，对随机对照试验进行风险评估，并应用该软件进行Meta分析。结果:共纳入7个随机对照试验，包括3 945例患者。Meta 分析结果显示:PD-1/PD-L1抑制剂在总生存期［HR=0.66，95%CI(0.61,0.72)，P＜0.000 01］、无进展生存期［HR=0.72，95%CI(0.59,0.87)，P=0.000 7］、总有效率［OR=1.91，95%CI(1.31,2.78)，P=0.000 7］方面均高于化疗对照组；任何级别不良反应事件［OR=0.32，95%CI(0.25,0.40)，P＜0.000 01］和3、4、5级不良反应事件［OR=0.23，95%CI(0.13,0.43)，P＜0.000 01］低于化疗对照组。结论:在中晚期NSCLC的治疗中，PD-1/PD-L1抑制剂的疗效以及安全性均优于化疗药物。
|
| 关 键 词： | PD-1/PD-L1抑制剂 非小细胞肺癌 化疗 随机对照试验 |
A Meta-analysis of efficacy and safety of PD-1/PD-L1 inhibitors for treatment of advanced non-small cell lung cancer |
| |
| Jiang Aimin,Cheng Yu. A Meta-analysis of efficacy and safety of PD-1/PD-L1 inhibitors for treatment of advanced non-small cell lung cancer[J]. Journal of Modern Oncology, 2020, 0(20): 3555-3560. DOI: 10.3969/j.issn.1672-4992.2020.20.019 |
| |
| Authors: | Jiang Aimin Cheng Yu |
| |
| Affiliation: | Medical Oncology，Affiliated Central Hospital of Shenyang Medical College，Liaoning Shenyang 110024,China. |
| |
| Abstract: | Objective:To systematically evaluate the efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of advanced non-small cell lung cancer(NSCLC).Methods:CNKI，Wanfang， Pubmed and Cochrane Library database were searched by computer.Researchers extracted data from the trials and checked them,and the Cochrane bias risk assessment tool of RevMan5.3 was used to conduct risk assessment of the randomized controlled trials.Meta analysis was also performed by this software.Results:A total of 7 randomized controlled trials were included,including 3 945 patients.Meta analysis results showed that PD-1/PD-L1 inhibitors were higher than the control group in the total survival period ［HR=0.66,95%CI(0.61,0.72),P＜0.000 01］,progression-free survival period［HR=0.72,95%CI(0.59,0.87),P=0.000 7］,and total effective rate［OR=1.91,95%CI(1.31,2.78),P=0.000 7］.Adverse events of any level ［OR=0.32,95%CI(0.25,0.40),P＜0.000 01］ and 3,4,5 adverse events［OR=0.23,95%CI(0.13,0.43),P＜0.000 01］ were lower than the control group.Conclusion:In the treatment of advanced NSCLC,the efficacy and safety of PD-1/PD-L1 inhibitors were superior to that of chemotherapy. |
| |
| Keywords: | PD-1/PD-L1 inhibitor non-small cell lung cancer chemotherapy randomized controlled trial |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载免费的PDF全文 |
|
